The clinical pharmacology of hexamethylmelamine: Phase I study

The human pharmacology for a new oncolytic agent, hexamethylmelamine, is described. The dose tolerated by 80 per cent of the population treated for 28 days was 10 mg. per kilogram per day. The principal adverse effects requiring discontinuation of therapy were gastroenteric and hematologic. Despite discontinuation of therapy, a latent effect associated with prolonged therapy was peripheral neuropathy, which was not reversible in some of the patients. No adverse drug effects on liver, renal, pulmonary, and cardiovascular function were observed.